Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS)
Post-hoc analysis
Post hoc
DOI:
10.1164/rccm.202312-2311oc
Publication Date:
2024-08-30T15:40:50Z
AUTHORS (14)
ABSTRACT
Chronic obstructive pulmonary disease (COPD) is associated with increased risk of cardiovascular and cardiopulmonary events. In the Phase III, 52-week ETHOS trial (NCT02465567), triple therapy budesonide/glycopyrrolate/formoterol fumarate (BGF) reduced rates moderate/severe exacerbations all-cause mortality versus dual glycopyrrolate/formoterol (GFF) or budesonide/formoterol (BFF). However, effect BGF on events GFF remains unevaluated. Further, time to first severe exacerbation has not been reported.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (53)
CITATIONS (9)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....